Elapegademase is a recombinant adenosine deaminase (rADA). It provides an exogenous source of ADA enzyme that is associated with a decrease in toxic adenosine and deoxyadenosine nucleotides levels as well as an increase in lymphocyte number. Severe combined immune deficiency (SCID) associated with a deficiency of ADA enzyme is a rare, inherited, and often fatal disease.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L03AX21 | L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AX Other immunostimulants | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| REVCOVI Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Elapegademase is an active ingredient of these brands:
United States (US)Japan (JP)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
